Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.77 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.63 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
| ▸ | IL1B | P01584 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922885 | 1.00 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20294602 | 1.00 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25574862 | 0.95 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23125090 | 0.94 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22150449 | 0.94 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23124945 | 0.94 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20294665 | 0.94 | CRBN (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20294668 | 0.94 | CRBN (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25358828 | 0.93 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23168707 | 0.93 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117836289-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use thereof | 上海睿跃生物科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117510491-A | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-110741004-B | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-113164775-A | Polycyclic compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3846907-A1 | POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| CN-110741004-A | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2020-01-31 | — | — | CN | disclosed |
| EP-3558994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| WO-2018119448-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | DDB1 384/4885CRBN 1/4885IKZF3 396/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | DDB1 384/4885CRBN 1/4885IKZF3 396/4885 |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | DDB1 133/4885CRBN 149/4885IKZF3 845/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | DDB1 384/4885CRBN 1/4885IKZF3 396/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | DDB1 384/4885CRBN 1/4885IKZF3 396/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | DDB1 384/4885CRBN 1/4885IKZF3 396/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | DDB1 399/4885CRBN 1/4885IKZF3 350/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | DDB1 384/4885CRBN 1/4885IKZF3 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.